Multidrug-resistant tuberculous meningitis

Current Neurology and Neuroscience Reports

Volumn 7, Issue 6, 2007, Pages 470-475

  Byrd, Thomas F ^a   Davis, Larry E ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GADOLINIUM; GATIFLOXACIN; GLUCOSE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; SODIUM; STREPTOMYCIN; THIOACETAZONE; TUBERCULIN;

ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APHASIA; ARACHNOIDITIS; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD CEREBROSPINAL FLUID BARRIER; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTRAST ENHANCEMENT; CRANIAL NERVE PARALYSIS; DROWSINESS; DRUG PENETRATION; FEVER; HEADACHE; HEMIPARESIS; HUMAN; HYDROCEPHALUS; HYPONATREMIA; IMMUNE DEFICIENCY; INCIDENCE; LABORATORY TEST; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; MALAISE; MENINGISM; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PAPILLEDEMA; PATHOGENESIS; PATIENT CARE; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; STUPOR; TUBERCULIN TEST; TUBERCULOUS MENINGITIS; UNITED STATES;

ANTIBIOTICS, ANTITUBERCULAR; BRAIN; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; DIAGNOSTIC IMAGING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MENINGES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MENINGEAL;

EID: 36148941065     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0073-8     Document Type: Review

References (46)

1. Ormerod LP: Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005, 73&74:17-24.
2. Centers for Disease Control: Trends in tuberculosis incidence-United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:245-250.
3. Centers for Disease Control: Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006, 55:1176.
4. Centers for Disease Control: Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305.
5. Zignol M, Hosseini MS, Wright A, et al.: Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:497-485.
6. Daley CL, Small PM, Schecter GF, et al.: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992, 326:231-235.
7. Goldfield A, Ellner JJ: Pathogenesis and management of HIV/TB co-infection in Asia. Tuberculosis (Edinb) 2007, In press.
8. Fischl MA, Uttamchandani RB, Daikos GL, et al.: An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992, 117:177-183.
9. Patel VB, Padayatchi N, Bhig;jee AL, et al.: Multidrug-resistant tuberculous meningitis in KwaZutu-Natal, South Africa. Clin Infect Dis 2004, 38:851-856.
10. Caws M, Thwaites GE, Duy PM, et al.: Molecular analysis of Mycobacterium tuberculosis causing multidrug-resistant tuberculosis meningitis. Int J Tuberc Lung Dis 2007, 11:202-208.
11. De Vincenzo JP, Berning SE, Peloquin CA, Husson RN: Multidrug-resistant tuberculous meningitis: Clinical problems and concentrations of second-line antituberculous medications. Ann Pharmacotber 1999, 33:1184-1188.
12. Kang PB, Azad AK, Torrelles JB, et al.: The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005, 202:987-999.
13. Ming T, Chakravarty S, Zhu G, et al.: Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative oxygen tension. Cell Micro 2006, 8:218-232.
14. Park H, Guinn KM, Harrell MI, et al.: Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003, 48:833-843.
15. Porkert MT, Sotir M, Parrott-Moore P, Blumberg HM: Tuberculous meningitis at a large inner city medical center. Am J Med Sci 1997, 313:32S-331.
16. Girgis NL, Farid SZ, Mansour M, et al.: Tuberculous meningitis, Abbassia Fever Hospital - Naval medical research unit no. 3 - Cairo, Egypt, from 1976-1996. Am J Trop Hygiene 1998, 58:28-34.
17. Ciesielski SD: BCG vaccination and the PPD test: what the clinician needs to know. J Fam Pract 199S, 40:76-80.
18. Merritt HH, Fremont-Smith F: Cerebrospinal fluid in tuberculous meningitis. Arch Neurol Psychiatr 1933, 33:516-536.
19. Davis LE, Rastogi KR, Lambert LC, Skipper BJ: Tuberculous meningitis in the southwest United States. Neurology 1993, 43:1775-1778.
20. Gupta RK, Gupta S, Singh D, et al.: MR imaging and angiography in tuberculous meningitis. Neuroradiology 1984, 36:87-92.
21. Srikanth SG, Taly AB, Nagarajan K, et al.: Clinicoradiological features of tuberculous meningitis in patients over 50 years of age. J Neurol Neurosurg Psychiatr 2007, 78:536-538.
22. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR: Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997, 99:226-231.
23. Davis LE: Subacute and chronic meningitis. Continuum 2006, 12:27-57.
24. Pfyffer GE, Kissling P, Jahn EM, et al.: Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J Clin Microbiol 1996, 34:834-841.
25. Kennedy DH, Fallon RJ: Tuberculous meningitis. J Am Med Assoc 1979, 241:264-268.
26. Zhao JR, Bai YJ, Wang Y, et al.: Development of pyrosequencing approach for rapid screening of rifampin, isoniazid and ethambutol-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2005, 9:328-332.
27. Kox LF, Kuijper S, Kolk AH: Early diagnosis of tuberculous meningitis by polymerase chain reaction. Neurology 1995, 45:2228-2232.
28. Kruuner A, Yates MD, Drobniewski FA: Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006, 44:811-817.
29. Tenover FC: Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 2007, 44:418-423.
30. Thwaites GE, Lan N, Dung N, et al.: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004, 351:1741-1751.
31. Iseman MD: Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993, 329:784-791.
32. Thwaites GE, Lan N, Dung N, et al.: Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005, 192:79-88.
33. Dorman SE, Chaisson RE: From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007, 13:295-298.
34. World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis. 2006. Available at http://www.who.int/tb. Accessed July 1, 2007.
35. Caminero JA: Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006, 10:829-837.
36. Mukherjee JS, Rich ML, Socci AR, et al.: Programmes and principles in treatment of multidr-ug-resistant tuberculosis. Lancet 2004, 363:474-481.
37. Furin J: The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007, 13:212-217.
38. Raviglione MC, Smith IM: XDR tuberculosis - implications for global public health. N Engl J Med 2007, 356:656-659.
39. Shah N, Wright A, Bai G, et al.: Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007, 13:380-387.
40. Nuermberger E, Rosenthal I, Tyagi S, et al.: Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006, 50:2621-2625.
41. Andries K, Verhasselt P, Guillemont J, et al.: A diaryquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
42. du Toit LC, Pillay V, Danckwerts MP: Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 2006, 7:118-136.
43. Lamprecht D, Schoeman J, Donald P, Hartzenberg H: Ventriculoperitoncal shunting in childhood tuberculosis meningitis. Br J Neurosurg 2001, 15:119-125.
44. Kent SJ, Crowe SM: Tuberculous meningitis: a 30 year review. Clin Infect Dis 1993, 17:987-994
45. Kalita J, Misra UK, Ranjan P: Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol 2007, 14:33-37.
46. Dube MP, Holtom PD, Larsen RA: Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med 1992, 93:520-524.